Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a)

AIMS: Elevated lipoprotein(a) [Lp(a)] is strongly associated with an increased cardiovascular disease (CVD) risk. We previously reported that pro-inflammatory activation of circulating monocytes is a potential mechanism by which Lp(a) mediates CVD. Since potent Lp(a)-lowering therapies are emerging,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur Heart J
Egile Nagusiak: Stiekema, Lotte C A, Prange, Koen H M, Hoogeveen, Renate M, Verweij, Simone L, Kroon, Jeffrey, Schnitzler, Johan G, Dzobo, Kim E, Cupido, Arjen J, Tsimikas, Sotirios, Stroes, Erik S G, de Winther, Menno P J, Bahjat, Mahnoush
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Clinical Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7308540/
https://ncbi.nlm.nih.gov/pubmed/32268367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehaa171
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak